[Thrombolysis in the acute stage of myocardial infarction].
The authors recall the conditions in which intravenous thrombolysis is justified, and the mode of action of the various thrombolytic products. They show the efficacy and the utility of thrombolysis and also its complications. The success of this treatment is closely linked to the time interval after thrombosis, which should be reduced as much as possible.
Dereppe
H
H
Hôpital Universitaire Saint Pierre, Service de Médecine Interne, Bruxelles.
Renard
M
M
Bernard
R
R
D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000627:therapeutic use; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
La thrombolyse à la phase aiguë de l'infarctus du myocarde.